ResMed’s heart failure trial disappoints

A disappointing clinical trial result has wiped some shine from ResMed's share price but the case to Hold remains.

In our update on ResMed’s recent third-quarter result we warned that there would be some fireworks in ResMed’s share price when the results of its SERVE-HF clinical trial were to be announced later this year. Well they’ve been reported early and the news is not good.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles